CytoReason

How do you build AI at scale in drug development? Start by ingesting massive amounts of standardized data across multiple modalities, building a pre-computed disease model, and making that model accessible to pharma enterprises via a platform and API. Now, imagine scaling these models across many diseases and hundreds of decisions – involving target prioritization, indication expansion and patient stratification – that impact entire drug portfolios. This is where R&D efforts can truly scale, and this is exactly the platform we're building at CytoReason. Our Chief Scientist, Shai Shen-Orr, recently discussed our work at NVIDIA's GTC conference, on a panel exploring how AI can reshape healthcare's future. Jump to timestamp to here: https://lnkd.in/dN6Q8Xwg And find out more about our disease models here: https://lnkd.in/dzRwhD3N Chelsea Sumner, PharmD, Rph - NVIDIA Cony D'Cruz - Superluminal Medicines Inc. Alessandro De Sario - Therapyside Davide Tricarico - AITEM Artificial Intelligence Technologies Multipurpose

What are the two biggest problems today in drug development? At NVIDIA's GTC conference co-founder Shai Shen-Orr answered this: a.    Our industry still doesn’t fully understand the nuances of disease biology b.    Human populations are far more diverse than we could ever imagine — we're not lab mice 😀 Both of these challenges impact efficacy success rates in clinical trials, where variability in treatment responses first emerge. To address these challenges, CytoReason’s disease models generate insights that help pharma leaders understand both disease biology and subpopulations. This enables them to make data-driven portfolio decisions throughout the entire drug development lifecycle. Learn more about CytoReason's disease models here: https://lnkd.in/duxS9p9z

Our team is heading to NVIDIA's GTC conference! To learn how CytoReason's AI models are improving efficacy success in drug development, please reach out to Chief Business Officer Nicole van Poppel, PhD and VP of Business Development & Sales, Tim O'Brien. And for a deeper dive into the impact generative AI and foundational models are making on the industry, come hear our Chief Scientist Shai Shen-Orr at the Inception Startups Conference session: Create, Cure, Care: Reimagining Healthcare — Driving Innovation From Ideation with AI Monday Mar 17 | 10:00 PM - 10:40 PM IST

A video is worth a thousand words 👏 Best Purim party ever 🎉 Tons of laughter, insane costumes, cocktails, delicacies—everything was amazing 🙌 Thanks Tali Bonjack, Shahar Schlimoff, and especially Renana Chechiqe for orchestrating this unforgettable masterpiece! Happy Purim 🥳

What a CytoPurim celebration! CytoReason 🎭🎁🎉🥁 Yesterday, we gave our employees a break from the daily routine with two hours of pure fun! a cocktail bar, a market-style food table, a selfie station, a DJ, an auction, and a crazy costume contest between departments! 🥂🎶🎭 The space was full of colors, energy, and good vibes, letting everyone get creative, have fun, and enjoy the moment. Seeing people laugh, drink, and celebrate together reminded me why I love what I do—creating experiences that bring people together and make work more enjoyable. 💙 A huge thank you to everyone who joined, participated, and made this event unforgettable, as well as to the amazing vendors I worked with!Can’t wait for the next one! 🚀

On International Women’s Day, and on any other day, we remind ourselves that skills and expertise are not defined by gender. We’re proud to work in a company where women make up half of our workforce and management team. To mark the occasion, we asked the men and women of CytoReason how they feel about International Women’s Day. Should companies like ours acknowledge this day? And how can we promote equality at CytoReason beyond just one passing day? We want to thank everyone who shared their thoughts with us—your voices matter. We also recognize that both the world and our company still have a way to go in achieving true equality, but we’re up for the challenge. Here’s what our people had to say.

Season 2 of ‘Tech on Drugs’ features a world-class lineup of industry leaders: Eran Segal (Weizmann Institute of Science): A computational biologist who was senior advisor to the Israeli government on COVID-19. Eran's lab published over 200 papers on nutrition, genetics, the microbiome, and gene regulation 💪 Tom Bumol (Eli Lilly and Company, Allen Institute): A serial drug developer, who helped develop GLP-1 receptor agonists, and whose team created over 100 drug candidates—including 11 FDA-approved treatments 👏 Asya Rolls (Technion - Israel Institute of Technology): A creative psychoneuroimmunologist who flipped the script—studying how the brain influences the immune system rather than the other way around 💡 Yair Benita (AION Labs): A prominent computational biologist who led teams at Merck, Compugen, and CytoReason. Yair passionately mapped out pharma’s "Kodak moments"—including the evolution of Keytruda, Merck's blockbuster cancer drug 📸 Shai Shen-Orr (CytoReason and Technion): A world-renowned expert in systems immunology and precision medicine. As host of ‘Tech on Drugs,’ Shai guides these conversations with his signature wit and depth, making the complex feel intuitive, and connecting insights to concrete outcomes for companies and patients 🎯 Listen to the full episodes here: https://lnkd.in/d2spBWnG

Great news! Co-founder and Chief Scientist Shai Shen-Orr has been promoted to Full Professor at the Technion - Israel Institute of Technology! Congrats, Shai 👏🎉 Truly inspiring to see so many familiar faces from CytoReason who traveled with you on this exciting journey.

If you’re heading to Cornell Tech’s HealthNext Summit next week, let’s connect! Ian Chiang, Alexandra Berk King, Jonathan Carlson, Shane Woods, Ph.D. Technion - Israel Institute of Technology, Zimin Institutes, CytoReason